RxDoctor Payments Data

Christian Khoury, MD

Hematology & Oncology · Quincy, ILNPI 1477694867

Payments from drug & device makers

$559,295in general payments, 2019–2025

Across 494 payments — averaging $1132.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$491K
  • Genentech, Inc.$49K
  • E.r. Squibb & Sons, L.L.C.$12K
  • Regeneron$2K
  • AstraZeneca$582
  • Novartis$445
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$5,57694%
  • Education$3516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$559,295 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$3,091,418
Medicare patients
563
Services billed
153,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate34$503,159
JakafiRuxolitinib Phosphate31$416,945
Lenalidomide17$323,390
ErleadaApalutamide21$313,799
PomalystPomalidomide12$270,889
VenclextaVenetoclax18$266,920
BosulifBosutinib11$207,494
BrukinsaZanubrutinib14$147,105
XareltoRivaroxaban93$69,156
EliquisApixaban100$65,928
Imatinib Mesylate13$3,990
Abiraterone Acetate16$3,852
Varenicline Tartrate18$3,706
Anagrelide Hcl17$1,181
Letrozole91$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$582$503,15934 claims
Incyte CorporationJakafi$70$416,94531 claims
Johnson & JohnsonErleada, Xarelto$361$382,955114 claims
PfizerBosulif, Eliquis$245$273,422111 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$11,928$270,88912 claims
AbbVieVenclexta$123$266,92018 claims
Lilly USA, LLCOlanzapine$203$36814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Quincy

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →